Wound Care, Tissue Repair & Regenerative Medicine

Biography

Biography: Claudia F Benjamim

Abstract

Statement of the problem: Chronic wound is a public health problem worldwide, which aff ects 6.5 million patients in USA. Such problem, in association with high global prevalence of diabetes, refl ects the increase in diabetic ulcers. Considering the absence of an eff ective treatment for chronic wound, the purpose of this study is to investigate the possible benefi cial eff ects of a purinergic agonist in tissue repair of chronic wounds in diabetic mice. Methodology: Diabetics was induced by Aloxan (75 mg/Kg I.V). Seven days later mice were anesthetized and a full-thickness wound was induced surgically using a punch biopsy (1 cm of diameter). ADP (30 μM) was topically applied once a day for 5 days consecutively on the wound. Findings: We observed that ADP accelerated the wound contraction, improved tissue repair, increased collagen deposition and recruited neutrophils and eosinophils to the wound. Also, ADP increased the number of mast cells and myofi broblasts in the wound. Besides, ADP positively modulated its own receptors, VEGF and TGF-α in the wound. Th ese eff ects were only observed in diabetic mice. More interestingly, others nucleotides did not accelerate the wound healing as ADP. Clopidogrel treatment, a P2Y12 receptor antagonist, prevented all parameters evaluated, confi rming the role of the P2Y12 in ADP eff ects. Still, ADP seemed to increase the number of arginase+ cells and to reduce iNOS+ cells, which implies in the increase of M2 macrophages in the wound. In in vitro experiments, ADP increased fi broblasts proliferation and migration, which corroborate with the in vivo studies. Finally, ADP also accelarated the S. aureus-infected wound healing. Conclusion & Signifi cance: ADP seems to modulate cell activation and recruitment providing an adequate scenario for wound healing in diabetic mice, being. It seems to be a promising treatment for chronic wounds.